Literature DB >> 10667567

Prognostic significance of cyclin E overexpression in resected non-small cell lung cancer.

T Fukuse1, T Hirata, H Naiki, S Hitomi, H Wada.   

Abstract

Cyclin E plays a pivotal role in the regulation of G1-S transition and relates to malignant transformation of the cells. However, the clinical significance of cyclin E expression in patients with non-small cell lung cancer remains unknown. We examined the expression of cyclin E in 242 resected non-small cell lung cancer in pathological stages I-IIIa and analyzed its relation to clinicopathological factors. Cylin E overexpressions were observed frequently in deeply invasive tumors. Multivariate analysis revealed that complete resection, pathological stage, and cyclin E expression were independent prognostic indicators. When cyclin E and proliferating cell nuclear antigen are combined, the cases negative for both had a significantly better prognosis than the other cases. We concluded that cyclin E overexpression relates to deeply invasive tumors and is correlated with poor prognosis. New therapeutic options may be provided by combination of cyclin E expression and proliferating cell nuclear antigen overexpression.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10667567

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  27 in total

1.  DDX3 regulates cell growth through translational control of cyclin E1.

Authors:  Ming-Chih Lai; Wen-Cheng Chang; Sheau-Yann Shieh; Woan-Yuh Tarn
Journal:  Mol Cell Biol       Date:  2010-09-13       Impact factor: 4.272

Review 2.  Cell cycle control as a basis for cancer chemoprevention through dietary agents.

Authors:  Syed Musthapa Meeran; Santosh Kumar Katiyar
Journal:  Front Biosci       Date:  2008-01-01

Review 3.  Immunohistochemical markers of prognosis in non-small cell lung cancer: a review and proposal for a multiphase approach to marker evaluation.

Authors:  C-Q Zhu; W Shih; C-H Ling; M-S Tsao
Journal:  J Clin Pathol       Date:  2006-08       Impact factor: 3.411

4.  Targeting the cyclin E-Cdk-2 complex represses lung cancer growth by triggering anaphase catastrophe.

Authors:  Fabrizio Galimberti; Sarah L Thompson; Xi Liu; Hua Li; Vincent Memoli; Simon R Green; James DiRenzo; Patricia Greninger; Sreenath V Sharma; Jeff Settleman; Duane A Compton; Ethan Dmitrovsky
Journal:  Clin Cancer Res       Date:  2009-12-22       Impact factor: 12.531

Review 5.  Low-Molecular-Weight Cyclin E in Human Cancer: Cellular Consequences and Opportunities for Targeted Therapies.

Authors:  Joseph A Caruso; Mylinh T Duong; Jason P W Carey; Kelly K Hunt; Khandan Keyomarsi
Journal:  Cancer Res       Date:  2018-09-07       Impact factor: 12.701

6.  CBX7 is a tumor suppressor in mice and humans.

Authors:  Floriana Forzati; Antonella Federico; Pierlorenzo Pallante; Adele Abbate; Francesco Esposito; Umberto Malapelle; Romina Sepe; Giuseppe Palma; Giancarlo Troncone; Marzia Scarfò; Claudio Arra; Monica Fedele; Alfredo Fusco
Journal:  J Clin Invest       Date:  2012-01-03       Impact factor: 14.808

7.  A carbazole alkaloid deactivates mTOR through the suppression of rictor and that induces apoptosis in lung cancer cells.

Authors:  Priyajit Chatterjee; Soma Seal; Sandip Mukherjee; Rakesh Kundu; Mantu Bhuyan; Nabin C Barua; Pranab K Baruah; Santi Prasad Sinha Babu; Samir Bhattacharya
Journal:  Mol Cell Biochem       Date:  2015-04-17       Impact factor: 3.396

8.  Dinaciclib Induces Anaphase Catastrophe in Lung Cancer Cells via Inhibition of Cyclin-Dependent Kinases 1 and 2.

Authors:  Alexey V Danilov; Shanhu Hu; Bernardo Orr; Kristina Godek; Lisa Maria Mustachio; David Sekula; Xi Liu; Masanori Kawakami; Faye M Johnson; Duane A Compton; Sarah J Freemantle; Ethan Dmitrovsky
Journal:  Mol Cancer Ther       Date:  2016-08-22       Impact factor: 6.261

9.  Comparing histone deacetylase inhibitor responses in genetically engineered mouse lung cancer models and a window of opportunity trial in patients with lung cancer.

Authors:  Tian Ma; Fabrizio Galimberti; Cherie P Erkmen; Vincent Memoli; Fadzai Chinyengetere; Lorenzo Sempere; Jan H Beumer; Bean N Anyang; William Nugent; David Johnstone; Gregory J Tsongalis; Jonathan M Kurie; Hua Li; James Direnzo; Yongli Guo; Sarah J Freemantle; Konstantin H Dragnev; Ethan Dmitrovsky
Journal:  Mol Cancer Ther       Date:  2013-05-16       Impact factor: 6.261

10.  Cyclin E deregulation is an early event in the development of breast cancer.

Authors:  Alexandra Shaye; Aysegul Sahin; Qiang Hao; Kelly Hunt; Khandan Keyomarsi; Isabelle Bedrosian
Journal:  Breast Cancer Res Treat       Date:  2008-12-24       Impact factor: 4.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.